Dyadic International (DYAI) Other Accumulated Expenses (2019 - 2025)
Dyadic International (DYAI) posted Other Accumulated Expenses of $20013.0 for Q1 2025, up 76.17% sequentially from $11360.0 in Q4 2024, and down 87.09% YoY from $155020.0 in Q1 2024.
Dyadic International (DYAI) Other Accumulated Expenses (2019 - 2025) Analysis & Trends
Dyadic International has reported Other Accumulated Expenses for 7 years, with the latest figure at $20013.0 in Q1 2025.
- Quarterly Other Accumulated Expenses fell 87.09% year-over-year to $20013.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $20013.0 (down 87.09% YoY) and the FY2024 annual result came in at $11360.0, changed 0.0% from the prior year.
- Other Accumulated Expenses rose to $20013.0 in Q1 2025 per DYAI's latest filing, from $11360.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $155020.0 in Q1 2024 and troughed at $11360.0 in Q4 2023.
- A 5-year average of $63499.4 and a median of $81618.0 in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2025: Other Accumulated Expenses surged 719.57% in 2021, then plunged 87.09% in 2025.
- Over 5 years, Other Accumulated Expenses stood at $109552.0 in 2021, then tumbled by 71.37% to $31360.0 in 2022, then sank by 63.78% to $11360.0 in 2023, then changed by 0.0% to $11360.0 in 2024, then jumped by 76.17% to $20013.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $20013.0, $11360.0, and $11360.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 20,013.00 |
| Dec 31, 2024 | 11,360.00 |
| Sep 30, 2024 | 11,360.00 |
| Mar 31, 2024 | 155,020.00 |
| Dec 31, 2023 | 11,360.00 |
| Sep 30, 2023 | 12,547.00 |
| Jun 30, 2023 | 90,683.00 |
| Mar 31, 2023 | 87,276.00 |
| Dec 31, 2022 | 31,360.00 |
| Sep 30, 2022 | 94,810.00 |
| Jun 30, 2022 | 81,618.00 |
| Dec 31, 2021 | 109,552.00 |
| Sep 30, 2021 | 86,770.00 |
| Jun 30, 2021 | 88,310.00 |
| Mar 31, 2021 | 60,452.00 |
| Dec 31, 2020 | 13,367.00 |
| Dec 31, 2019 | 21,820.00 |